PSPiotr Starnawski

Piotr Starnawski

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Piotr Starnawski has a total of 12 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Environmental and socioeconomic factors influencing hepatotropic virus transmission

    by Wiktoria Bisaga, Monika Wieczorek, Jakub Pawliński, Dominik Malicki, Piotr Starnawski, Kamil Jonczyk, Jakub Janczura

    Background: Viral hepatitis remains a major public health concern worldwide. In 2022 alone, it accounted for approximately 1.3 million deaths, with hepatitis B (HBV) and hepatitis C viruses (HCV) responsible for the majority. However, hepatitis A (HAV) and hepatitis E (HEV) viruses continue to cause significant outbreaks, especially in settings with poor sanitation, while hepatitis D virus contributes to more severe outcomes in individuals with HBV. The burden of these infections is disproportionately high in low- and middle-income countries, where socioeconomic disparities, environmental conditions, and healthcare limitations hinder prevention and control efforts. Aims of the study: This review aims to analyze environmental and socioeconomic factors influencing the global prevalence and transmission dynamics of these infections.Material and methods: A comprehensive English-language literature review was conducted using PubMed, Scopus, and the World Health Organization databases, focusing on articles published between January 1, 2012, and May 28, 2025. From an initial pool of 437 articles, 44 articles and 8 reports were included for detailed analysis.Results: Environmental determinants such as inadequate sanitation, poor water quality, and overcrowding significantly contribute to HAV and HEV outbreaks, particularly in low-income countries. Socioeconomic factors, including poverty, limited healthcare access, and education gaps, exacerbate HBV and HCV spread via unsafe medical practices and needle sharing. Displacement and migration amplify the vulnerability of at-risk populations, especially in regions with endemic viral hepatitis. Innovative technologies, including direct-acting antivirals for HCV and vaccines like Hecolin for HEV, have shown promise but face challenges in accessibility and affordability.Conclusions: This study underscores the critical connection of environmental and socioeconomic factors in shaping the burden of hepatotropic viruses globally. Targeted public health interventions, improved healthcare access, and policy frameworks are essential to reduce transmission and achieve WHO's 2030 elimination targets for HBV and HCV.

  • The association between cardiovascular complications of chronic hepatotropic viral infection: a narrative review of pathophysiological pathways

    by Klaudia Nowak, Krzysztof Łupina, Weronika Stępień, Piotr Starnawski, Kamil Jonczyk, Jakub Janczura

    BackgroundChronic hepatotropic viral infections are a global health burden due to their prevalence and systemic impacts. Usually associated with hepatic complications, new evidence indicates that these infections also contribute to cardiovascular diseases (CVD). The mechanisms underlying these associations involve direct viral effects, chronic inflammation, immune dysregulation, and metabolic alterations.Aim of the StudyThis review aims to explore the pathophysiological mechanisms by which chronic hepatotropic viral infections influence cardiovascular health, assess the clinical implications and highlight strategies for managing cardiovascular risks.Material and MethodsA literature review was conducted using the search terms Hepatitis B AND cardiovascular disease, Hepatitis C AND cardiovascular risk, Hepatitis D AND atherosclerosis, Hepatitis E AND cardiac complications, Chronic viral hepatitis AND myocardial infarction on PubMed (articles published from January 1, 2009 through January 1, 2025), National Institutes of Health (NIH) (articles published from January 1, 2009 through January 1, 2025), and the World Health Organization (WHO) data.ResultsHepatitis C virus contributes significantly to atherosclerosis through endothelial dysfunction and chronic inflammation. For hepatitis B virus (HBV), the association with CVD remains inconclusive. Some studies suggest that HBV promotes oxidative stress and macrophage phenotypic changes conducive to atherosclerosis, others report no cardiovascular impact. Hepatitis D virus coinfection amplifies systemic inflammation, inducing cytokine storms and exacerbating vascular damage. Hepatitis E virus has been linked to arrhythmias, thrombosis, and endothelial dysfunction in immunocompromised patients.ConclusionsHepatotropic viral infections pose risks to cardiovascular health through direct and indirect mechanisms. Antiviral therapies have transformed the management of HCV and HBV, but their cardiovascular implications necessitate monitoring and intervention strategies. Screening, effective antiviral treatment, and targeted lifestyle modifications are critical for mitigating cardiovascular risks.


  • Role of hepatotropic viruses in promoting hepatocellular carcinoma—current knowledge and recent advances

    by Piotr Starnawski, Klaudia Nowak, Zuzanna Augustyn, Dominik Malicki, Aleksandra Piąta, Dominika Lorek, Jakub Janczura

    Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality worldwide, with chronic infections by hepatotropic viruses such as hepatitis B virus (HBV), and hepatitis C virus (HCV), being major risk factors. Chronic infections with these viruses are the leading cause of HCC worldwide, with HBV alone responsible for over 50% of cases. Despite advances in direct-acting antivirals (DAAs) for HCV and nucleos(t)ide analogues (NAs) for HBV, challenges remain in HCC prevention, early detection, and treatment. Recent research highlights the role of viral-induced metabolic alterations, such as the Warburg effect, mitochondrial dysfunction, and lipid dysregulation, in promoting HCC. Moreover, immune checkpoint inhibitors have emerged as effective treatments for advanced HCC, though responses vary between HBV- and HCV-related cancers. Additionally, novel therapeutic approaches and metabolic-targeted therapies offer promising avenues for virus-associated HCC treatment. Advancements in liquid biopsy biomarkers and artificial intelligence-driven diagnostics are improving HCC surveillance and risk stratification, potentially enabling earlier interventions. While HBV vaccination has significantly reduced HCC incidence, disparities in global vaccination coverage persist. Furthermore, antiviral therapies combined with structured surveillance programs have proven effective in reducing HCC incidence and mortality. This review highlights the complex connection between viral, genetic, and environmental factors in HCC development and underscores the importance of integrated prevention strategies to reduce its burden globally.